Evidence map›Paper›PMID 40715929›Full record

ReviewInflammopharmacology2025

Is dolichol pathway dysfunction a significant factor in Alzheimer's disease?

John V Schloss

Abstract readReview
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

John V SchlossDepartments of Pharmaceutical Science and Biochemistry and Molecular Biology, Schools of Pharmacy and Medicine, American University of Health Sciences, 1600 East Hill St., Signal Hill, CA, 90755, USA. jschloss@auhs.edu.ORCID http://orcid.org/0000-0002-6586-7508

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several lines of evidence point to defects in the dolichol pathway as a major contributor to the development of Alzheimer's disease and inflammation associated with the unfolded protein response. In particular, zinc deficiency impairs formation of dolichol phosphate and low levels of pyridine nucleotides (NAD or NADPH), due to niacin deficiency, result in reduced conversion of polyprenol to dolichol phosphate, leading to reduced N-glycosylation of proteins. The magnesium-dependent transfer of N-acetyl-D-glucosamine-1-phosphate between dolichol phosphate (necessary for N-glycosylation) and UMP (required for O-glycosylation) by DPAGT1 ties dolichol phosphate biosynthesis to the balance between O- and N-glycosylation. Alteration of protein glycosylation would affect the folding, function, and physical properties (e.g., solubility) of many glycoproteins, such as UDP-glucuronosyltransferase (anosmia), amyloid precursor protein, tau, acetylcholine receptors, ligand-gated ion channels, voltage-gated ion channels, and G protein-coupled receptors. Three of the five best documented stress-induced nutritional deficiencies (i.e., zinc, niacin, and magnesium) would contribute to alterations in glycosylation of these and many other proteins involved in the progression of Alzheimer's disease.

Indexed as

Alzheimer DiseaseDolicholsAnimalsGlycosylationHumansUnfolded Protein ResponseDolicholsAlzheimer’s diseaseDolichol phosphateMagnesiumN- and O-glycosylationNiacinZinc

Identifiers

PMID40715929
PMCPMC12397121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.